Iterum stock rallies 54% on FDA approval of Orlynvah for UTIs

seekingalpha10-26

Bet_Noire Iterum Therapeutics (NASDAQ:ITRM) stock shot up 54% Friday after the company received FDA approval for its drug Orlynvah for the treatment of uncomplicated urinary tract infections, or uUTIs...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2478639509?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215516118/image_1215516118.jpg?io=getty-c-w750","is_english":true,"pubTime":"2024-10-26 03:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2478639509","market":"hk","top_or_hot":-1,"title":"Iterum stock rallies 54% on FDA approval of Orlynvah for UTIs","media":"seekingalpha","content":"<div>\n<p>Bet_Noire Iterum Therapeutics (NASDAQ:ITRM) stock shot up 54% Friday after the company received FDA approval for its drug Orlynvah for the treatment of uncomplicated urinary tract infections, or uUTIs...</p>\n\n<a href=\"https://seekingalpha.com/news/4206808-iterum-stock-rallies-on-fda-approval-of-olynvah-for-utis\">Source Link</a>\n\n</div>\n","source":"seekingalpha_trending_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Iterum stock rallies 54% on FDA approval of Orlynvah for UTIs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIterum stock rallies 54% on FDA approval of Orlynvah for UTIs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-26 03:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4206808-iterum-stock-rallies-on-fda-approval-of-olynvah-for-utis><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bet_Noire Iterum Therapeutics (NASDAQ:ITRM) stock shot up 54% Friday after the company received FDA approval for its drug Orlynvah for the treatment of uncomplicated urinary tract infections, or uUTIs...</p>\n\n<a href=\"https://seekingalpha.com/news/4206808-iterum-stock-rallies-on-fda-approval-of-olynvah-for-utis\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FT_SY_MNQ","symbol_name":"微型NQ100指数","start_time":0,"source_url":"https://seekingalpha.com/news/4206808-iterum-stock-rallies-on-fda-approval-of-olynvah-for-utis","article_id":"2478639509","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215516118/image_1215516118.jpg?io=getty-c-w750"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2478639509","pubTimestamp":1729883221,"sourceInfo":{"source_id":"seekingalpha_trending_news","name":"Seeking Alpha Trending News"},"weMediaInfo":null,"summary":"Bet_Noire Iterum Therapeutics (NASDAQ:ITRM) stock shot up 54% Friday after the company received FDA approval for its drug Orlynvah for the treatment of uncomplicated urinary tract infections, or uUTIs. The drug, which is Iterum’s first FDA-approved product, is indicated for treatment of uUTIs","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"QID":"纳指两倍做空ETF","PSQ":"纳指反向ETF","ITRM":"Iterum Therapeutics Plc","SQQQ":"纳指三倍做空ETF","QLD":"纳指两倍做多ETF",".IXIC":"NASDAQ Composite","TQQQ":"纳指三倍做多ETF","BK4007":"制药"},"translate_title":"FDA批准Orlynvah治疗尿路感染，Iterum股价上涨54%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ITRM":0.9,".IXIC":0.7,"MNQmain":0.6,"NQmain":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"SQQQ":0.6,"TQQQ":0.6},"content_text":"Bet_Noire Iterum Therapeutics (NASDAQ:ITRM) stock shot up 54% Friday after the company received FDA approval for its drug Orlynvah for the treatment of uncomplicated urinary tract infections, or uUTIs. The drug, which is Iterum’s first FDA-approved product, is indicated for treatment of uUTIs","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2478639509"}